Novo Nordisk introduces oral formulation of Wegovy weight-loss medication

Novo Nordisk has launched an oral tablet version of its semaglutide-based weight-loss drug, Wegovy, providing an alternative to injectable administration. While the pill addresses patient needle phobia, clinical efficacy and safety profiles compared to the injectable version remain the primary focus for medical oversight.